Literature DB >> 23456229

Dysregulation of FHL1 spliceforms due to an indel mutation produces an Emery-Dreifuss muscular dystrophy plus phenotype.

Heather R Tiffin1, Zandra A Jenkins, Mary J Gray, Sophia R Cameron-Christie, Jennifer Eaton, Salim Aftimos, David Markie, Stephen P Robertson.   

Abstract

Emery-Dreifuss muscular dystrophy (EDMD) is characterised by early-onset joint contractures, progressive muscular weakness and wasting and late-onset cardiac disease. The more common X-linked recessive form of EDMD is caused by mutations in either EMD (encoding emerin) or FHL1 (encoding four and a half LIM domains 1), while mutations in LMNA (encoding lamin A/C), SYNE1 (encoding nesprin-1) and SYNE2 (encoding nesprin-2) lead to autosomal dominant forms of the condition. Here, we identify a three-generation family with an extended EDMD phenotype due to a novel indel mutation in FHL1 that differentially affects the relative expression of the three known transcript isoforms produced from this locus. The additional phenotypic manifestations in this family-proportionate short stature, facial dysmorphism, pulmonary valvular stenosis, thoracic scoliosis, brachydactyly, pectus deformities and genital abnormalities-are reminiscent of phenotypes seen with dysregulated Ras-mitogen-activated protein kinase (RAS-MAPK) signalling [Noonan syndrome (NS) and related disorders]. The misexpression of FHL1 transcripts precipitated by this mutation, together with the role of FHL1 in the regulation of RAS-MAPK signalling, suggests that this mutation confers a complex phenotype through both gain- and loss-of-function mechanisms. This indel mutation in FHL1 broadens the spectrum of FHL1-related disorders and implicates it in the pathogenesis of NS spectrum disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456229     DOI: 10.1007/s10048-013-0359-8

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  55 in total

1.  Noonan syndrome associated with moyamoya disease: report of one case.

Authors:  K T Tang; W Yang; J Wong; K Y Lee
Journal:  Acta Paediatr Taiwan       Date:  1999 Jul-Aug

2.  Notch signaling suppresses p38 MAPK activity via induction of MKP-1 in myogenesis.

Authors:  Kunio Kondoh; Kazunori Sunadome; Eisuke Nishida
Journal:  J Biol Chem       Date:  2006-12-07       Impact factor: 5.157

3.  Four and a half LIM protein 1: a partner for KCNA5 in human atrium.

Authors:  Zhenjiang Yang; Carrie F Browning; Haifa Hallaq; Liudmila Yermalitskaya; Jan Esker; Matthew R Hall; Andrew J Link; Amy-Joan L Ham; Meagan J McGrath; Christina A Mitchell; Katherine T Murray
Journal:  Cardiovasc Res       Date:  2008-02-15       Impact factor: 10.787

4.  KyoT3, an isoform of murine FHL1, associates with the transcription factor RBP-J and represses the RBP-J-mediated transactivation.

Authors:  Liang Liang; Hong-Wei Zhang; Jie Liang; Xiao-Li Niu; Su-Zhen Zhang; Lei Feng; Ying-Min Liang; Hua Han
Journal:  Biochim Biophys Acta       Date:  2008-08-09

5.  Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1).

Authors:  E K Ng; S M Lee; H Y Li; S M Ngai; S K Tsui; M M Waye; C Y Lee; K P Fung
Journal:  J Cell Biochem       Date:  2001 Apr 2-27       Impact factor: 4.429

6.  Moyamoya syndrome in a child with Noonan syndrome.

Authors:  Po-Cheng Hung; Huei-Shyong Wang; Alex M-C Wong
Journal:  Pediatr Neurol       Date:  2011-08       Impact factor: 3.372

7.  LIM protein KyoT2 negatively regulates transcription by association with the RBP-J DNA-binding protein.

Authors:  Y Taniguchi; T Furukawa; T Tun; H Han; T Honjo
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

8.  Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.

Authors:  Felix W Friedrich; Brendan R Wilding; Silke Reischmann; Claudia Crocini; Patrick Lang; Philippe Charron; Oliver J Müller; Meagan J McGrath; Ingra Vollert; Arne Hansen; Wolfgang A Linke; Christian Hengstenberg; Gisèle Bonne; Stellan Morner; Thomas Wichter; Hugo Madeira; Eloisa Arbustini; Thomas Eschenhagen; Christina A Mitchell; Richard Isnard; Lucie Carrier
Journal:  Hum Mol Genet       Date:  2012-04-20       Impact factor: 6.150

9.  A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations.

Authors:  Dong-Hui Chen; Wendy H Raskind; William W Parson; Joshua A Sonnen; Tiffany Vu; Yunlin Zheng; Mark Matsushita; John Wolff; Hillary Lipe; Thomas D Bird
Journal:  J Neurol Sci       Date:  2010-07-14       Impact factor: 3.181

Review 10.  Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

Authors:  D M Owens; S M Keyse
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

View more
  11 in total

1.  Fhl1 W122S causes loss of protein function and late-onset mild myopathy.

Authors:  Valentina Emmanuele; Akatsuki Kubota; Beatriz Garcia-Diaz; Caterina Garone; Hasan O Akman; Daniel Sánchez-Gutiérrez; Luis M Escudero; Shingo Kariya; Shunichi Homma; Kurenai Tanji; Catarina M Quinzii; Michio Hirano
Journal:  Hum Mol Genet       Date:  2014-09-30       Impact factor: 6.150

Review 2.  Nuclear membrane diversity: underlying tissue-specific pathologies in disease?

Authors:  Howard J Worman; Eric C Schirmer
Journal:  Curr Opin Cell Biol       Date:  2015-06-24       Impact factor: 8.382

3.  Loss of FHL1 induces an age-dependent skeletal muscle myopathy associated with myofibrillar and intermyofibrillar disorganization in mice.

Authors:  Andrea A Domenighetti; Pao-Hsien Chu; Tongbin Wu; Farah Sheikh; David S Gokhin; Ling T Guo; Ziyou Cui; Angela K Peter; Danos C Christodoulou; Michael G Parfenov; Joshua M Gorham; Daniel Y Li; Indroneal Banerjee; Xianyin Lai; Frank A Witzmann; Christine E Seidman; Jonathan G Seidman; Aldrin V Gomes; G Diane Shelton; Richard L Lieber; Ju Chen
Journal:  Hum Mol Genet       Date:  2013-08-23       Impact factor: 6.150

4.  Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice.

Authors:  Akatsuki Kubota; Martí Juanola-Falgarona; Valentina Emmanuele; Maria Jose Sanchez-Quintero; Shingo Kariya; Fusako Sera; Shunichi Homma; Kurenai Tanji; Catarina M Quinzii; Michio Hirano
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 5.121

Review 5.  The sarcomeric M-region: a molecular command center for diverse cellular processes.

Authors:  Li-Yen R Hu; Maegen A Ackermann; Aikaterini Kontrogianni-Konstantopoulos
Journal:  Biomed Res Int       Date:  2015-04-15       Impact factor: 3.411

Review 6.  Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

7.  Risk stratification in laminopathies and Emery Dreifuss muscular dystrophy.

Authors:  Abdallah Fayssoil
Journal:  Neurol Int       Date:  2018-04-04

8.  Role of Zebrafish fhl1A in Satellite Cell and Skeletal Muscle Development.

Authors:  F Chen; W Yuan; X Mo; J Zhuang; Y Wang; J Chen; Z Jiang; X Zhu; Q Zeng; Y Wan; F Li; Y Shi; L Cao; X Fan; S Luo; X Ye; Y Chen; G Dai; J Gao; X Wang; H Xie; P Zhu; Y Li; X Wu
Journal:  Curr Mol Med       Date:  2017       Impact factor: 2.222

9.  Whole-Genome Methylation Analysis of Phenotype Discordant Monozygotic Twins Reveals Novel Epigenetic Perturbation Contributing to the Pathogenesis of Adolescent Idiopathic Scoliosis.

Authors:  Gang Liu; Lianlei Wang; Xinyu Wang; Zihui Yan; Xinzhuang Yang; Mao Lin; Sen Liu; Yuzhi Zuo; Yuchen Niu; Sen Zhao; Yanxue Zhao; Jianguo Zhang; Jianxiong Shen; Yipeng Wang; Guixing Qiu; Zhihong Wu; Nan Wu
Journal:  Front Bioeng Biotechnol       Date:  2019-12-10

10.  Three novel FHL1 variants cause a mild phenotype of Emery-Dreifuss muscular dystrophy.

Authors:  Josefine D S Borch; Thomas Krag; Sonja D Holm-Yildiz; Hakan Cetin; Tuva A Solheim; Freja Fornander; Volker Straub; Morten Duno; John Vissing
Journal:  Hum Mutat       Date:  2022-07-16       Impact factor: 4.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.